The National Institute of Allergy and Infectious Diseases is expanding
its clinical trial of an experimental West Nile virus (WNV) treatment. The
trial opened at 36 sites last September, and it is expected to
add about 24 new sites this summer.
The trial is assessing the safety of a product containing WNV antibodies
derived from individuals who have high blood levels of these antibodies. These
antibodies may have the potential to help patients fight WNV infections.
Hampton T. West Nile Virus Trials. JAMA. 2004;292(8):916. doi:10.1001/jama.292.8.916-d